WEDNESDAY, Sept. 6, 2017 -- The inhaler medication Spiriva (tiotropium bromide) may help slow the progression of COPD if given in the early stages of the disease, a new study suggests. Researchers ...
SPIRIVA RESPIMAT Inhalation Spray is now available by prescription through retail pharmacies across the United States for the long-term, once-daily maintenance treatment of bronchospasm associated ...
Long-term, Head-to-Head Study Showed SPIRIVA HandiHaler (tiotropium bromide inhalation powder) Significantly Prolonged Time to First Moderate or Severe COPD Exacerbation versus Salmeterol HFA-MDI The ...
FDA recently accepted sNDA filing to review data from DYNAGITO trial for inclusion in Stiolto Respimat label A COPD exacerbation, or a flare-up, is a sudden worsening of symptoms, such as increased ...
-- Patients to Benefit From Easy-to-Use Inhaler With Enhanced Drug Delivery Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market ...
RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term ...
This approval was based on efficacy and safety data from the Phase 2 and Phase 3 UniTinA-asthma clinical development program. The Food and Drug Administration (FDA) has approved Spiriva Respimat ...
RIDGEFIELD, Conn., August 19, 2014 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose ...
RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--A new study, published today in The New England Journal of Medicine (NEJM), showed that SPIRIVA ® HandiHaler ® (tiotropium bromide inhalation powder), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback